Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > HISTORY

<< Previous

Bullboard Posts

Next >>

Post by THORZEUS2019on Feb 26, 2021 4:20pm

346 Views

Post# 32673824

HISTORY

Back on DEC 05/2017 , KLY opened at $0.27, had a high of $0.47 and closed at $0.34...39 million shares traded on TSXV..It went on to reach a high of $0.56 a month later..All this before R-107...Today we traded 49 million shares on the TSXV, over 70 million if you count all the exchanges. KLY has set a presidence and the world should be watching

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?